Gilead Files Single-Pill HCV Therapy In Japan
This article was originally published in PharmAsia News
Gilead Sciences Inc. has filed for the approval in Japan of what is poised to become the first single-pill regimen in the country for hepatitis C, a major public health problem.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.